Mark Worthington - 18 Jan 2022 Form 4 Insider Report for Athira Pharma, Inc. (ATHA)

Role
General Counsel
Signature
/s/ Glenna Mileson, Attorney-in-fact for Mark Worthington
Issuer symbol
ATHA
Transactions as of
18 Jan 2022
Net transactions value
$0
Form type
4
Filing time
20 Jan 2022, 16:27:24 UTC
Previous filing
05 Nov 2021
Next filing
24 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATHA Stock Option (Right to Buy) Award $0 +150,000 $0.000000 150,000 18 Jan 2022 Common Stock 150,000 $10.64 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One forty-eighth (1/48th) of the shares subject to the option will vest on February 18, 2022, and one forty-eighth of the shares subject to the option will vest each month thereafter.